Deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a single-institution retrospective dosimetric analysis of organs at risk doses
Abstract:Background
Radiotherapy can induce cardiac injury in left-sided breast cancer cases. Cardiac-sparing irradiation using the deep inspiration breath-hold (DIBH) technique can achieve substantial dose reduction to vulnerable cardiac substructures compared with free breathing (FB). This study evaluated the dosimetric differences between both techniques at a single institution.
Methods
From 2017 to 2019, 130 patients with left-sided breast cancer underwent brea… Show more
“…However, this effect was not as unequivocal as with the heart and the LAD, and it should be kept in mind that in a significant group of patients, DIBH plans were inferior to the FB technique in terms of the MLD and V20Gy. Some recent studies with significant groups of patients show similar results [5,[26][27][28]. In some patients with special concerns about lung toxicity, when DIBH is not sufficient to reduce the dose to the heart and the ipsilateral lung, radiotherapy in the prone position is a promising option [5].…”
“…However, this effect was not as unequivocal as with the heart and the LAD, and it should be kept in mind that in a significant group of patients, DIBH plans were inferior to the FB technique in terms of the MLD and V20Gy. Some recent studies with significant groups of patients show similar results [5,[26][27][28]. In some patients with special concerns about lung toxicity, when DIBH is not sufficient to reduce the dose to the heart and the ipsilateral lung, radiotherapy in the prone position is a promising option [5].…”
“…For spatial localization during each treatment, megavoltage electronic portal imaging or a similar imaging system was used. During the simulation process and each treatment session for patients with cancers of the left breast, deep inspiration breath-holding was recommended to reduce the dose delivered to the heart [ 15 , 16 ]; however, this was not essential, and free breathing was permitted in all cases.…”
Background
The applicability of ultra-hypofractionated (ultra-HF) whole-breast irradiation (WBI) remains unknown in Japanese women. This study aimed to evaluate the safety and efficacy of this approach among Japanese women and report the results of an interim analysis performed to assess acute adverse events (AEs) and determine whether it was safe to continue this study.
Methods
We enrolled Japanese women with invasive breast cancer or ductal carcinoma in situ who had undergone breast-conserving surgery, were aged ≥ 40 years, had pathological stages of Tis–T3 N0–N1, and had negative surgical margins. Ultra-HF-WBI was delivered at 26 Gy in five fractions over one week. When the number of enrolled patients reached 28, patient registration was paused for three months. The endpoint of the interim analysis was the proportion of acute AEs of grade ≥ 2 (Common Terminology Criteria for Adverse Events v5.0) within three months.
Results
Of the 28 patients enrolled from seven institutes, 26 received ultra-HF-WBI, and 2 were excluded due to postoperative infections. No AEs of grade ≥ 3 occurred. One patient (4%) experienced grade 2 radiation dermatitis, and 18 (69%) had grade 1 radiation dermatitis. The other acute grade 1 AEs experienced were skin hyperpigmentation (n = 10, 38%); breast pain (n = 4, 15%); superficial soft tissue fibrosis (n = 3, 12%); and fatigue (n = 1, 4%). No other acute AEs of grade ≥ 2 were detected.
Conclusions
Acute AEs following ultra-HF-WBI were within acceptable limits among Japanese women, indicating that the continuation of the study was appropriate.
“…For spatial localization during each treatment, megavoltage electronic portal imaging or a similar imaging system was used. During the simulation process and each treatment session for patients with cancers of the left breast, deep inspiration breath-holding was recommended to reduce the dose delivered to the heart [15,16]; however, this was not essential, and free breathing was permitted in all cases.…”
Background
The applicability of ultra-hypofractionated (ultra-HF) whole-breast irradiation (WBI) remains unknown in Japanese women. This study aimed to evaluate the safety and efficacy of this approach among Japanese women and report the results of an interim analysis performed to assess acute adverse events (AEs) and determine whether it was safe to continue this study.
Methods
We enrolled Japanese women with invasive breast cancer or ductal carcinoma in situ who had undergone breast-conserving surgery, were aged ≥ 40 years, had pathological stages of Tis–T3 N0–N1, and had negative surgical margins. Ultra-HF-WBI was delivered at 26 Gy in five fractions over one week. When the number of enrolled patients reached 28, patient registration was paused for three months. The endpoint of the interim analysis was the proportion of acute AEs of grade ≥ 2 (Common Terminology Criteria for Adverse Events v5.0) within three months.
Results
Of the 28 patients enrolled from seven institutes, 26 received ultra-HF-WBI, and 2 were excluded due to postoperative infections. No AEs of grade ≥ 3 occurred. One patient (4%) experienced grade 2 radiation dermatitis, and 18 (69%) had grade 1 radiation dermatitis. The other acute grade 1 AEs experienced were skin hyperpigmentation (n = 10, 38%); breast pain (n = 4, 15%); superficial soft tissue fibrosis (n = 3, 12%); and fatigue (n = 1, 4%). No other acute AEs of grade ≥ 2 were detected.
Conclusions
Acute AEs following ultra-HF-WBI were within acceptable limits among Japanese women, indicating that the continuation of the study was appropriate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.